Hennion & Walsh Asset Management Inc. grew its position in REGENXBIO Inc. (NASDAQ:RGNX – Free Report) by 8.6% during the 4th ...

REGENXBIO's partnership with Nippon Shinyaku provides $110M upfront, ensuring a cash runway for gene therapy programs in MPS ...

Regenxbio will receive $110m upfront from Nippon Shinyaku and is eligible to get up to $700m in development, regulatory, and ...

Regenxbio's rolling BLA submission completion of RGX-121 for the treatment of patients with MPS II expected in Q1 of 2025.

Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $39.0, along ...

With an FDA approval submission for RegenXBio’s Hunter syndrome gene therapy already underway, the biopharma has now ...

Analyst Yi Chen from H.C. Wainwright reiterated a Buy rating on RegenXBio (RGNX – Research Report) and keeping the price target at $36.00.Stay ...

K filing with the Securities and Exchange Commission (SEC) that the company has established a Collaboration and License Agreement with Nippon Shinyaku Co., Ltd. This collaboration focuses on the ...

Regenxbio, a prolific developer of gene therapy technology, will hand Japan’s Nippon Shinyaku certain rights to two ...

Rockville’s RegenxBio Inc. (NASDAQ: RGNX) has inked an agreement with a Japanese drug company to get two of its treatment candidates to market — a deal that could be worth $810 million over time.

Regenxbio has entered into a strategic collaboration worth $810m with Japan-based Nippon Shinyaku to advance gene therapies targeting the rare metabolic disorder mucopolysaccharidosis (MPS).

Stifel Nicolaus analyst Annabel Samimy has reiterated their bullish stance on RGNX stock, giving a Buy rating today.Stay Ahead of the ...